BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS and PI3Kα pathway cancers. The company specializes in precision oncology by creating innovative approaches to address historically difficult-to-drug targets, including direct KRAS inhibitors that bind to both active and inactive protein states, PI3Kα:RAS interaction breakers designed to block specific signaling cascades while minimizing metabolic side effects, and pan-KRAS inhibitors targeting multiple KRAS mutations. BridgeBio Oncology Therapeutics currently has multiple programs in clinical development, including candidates for non-small cell lung cancer, colorectal cancer, and breast cancer. Originally established as a subsidiary of BridgeBio Pharma in 2016, the company became a standalone public entity in 2025 through a business combination. Based in South San Francisco, BridgeBio Oncology Therapeutics applies advanced understanding of RAS signaling biology to rational drug design, aiming to deliver well-tolerated medicines with greater efficacy and safety for patients with cancers driven by the two most prevalent oncogenes in human tumors.